Jody speaks with Josh Bartch, CEO and director of Mydecine Innovations Group (MYCO.NEO), a psychedelics company focused on advancing its lead psilocybin drug candidate MYCO-001 into Phase II clinical trials for use in smoking cessation therapies.
Latest News
Soma Gold Corp (SOMA.V) drills, mills, and produces gold in Colombia
Quimbaya Gold’s (QIM.C) CEO will buy his stock if you won’t
Salt, hydrogen, or uranium? Atco Mining (ATCO.C) hits all three
Prospera Energy (PEI.V) goes to borrowers again as boe/d drops 20%
Argo Living Soils (ARGO.C) creates carbon rich biochar.. could that be turned into graphene?
Hemostenix (HEMO.V): Bringing back that lovin’ feeling.. and up 400% in a month
